dalfopristin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, streptogramins, protein-synthesis inhibitors, pristinamycin derivatives | 778 | 112362-50-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
component of RP-59500
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 4.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.20 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.39 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.82 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.74 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.03 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 21, 1999 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01FG02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Streptogramins |
| FDA CS | M0022748 | Streptogramins |
| FDA EPC | N0000175502 | Streptogramin Antibacterial |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Vancomycin resistant enterococcus | indication | 113727004 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
| Pyrexia of unknown origin | off-label use | 7520000 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.67 | acidic |
| pKa2 | 4.1 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4021183 | VUID |
| N0000179689 | NUI |
| D00853 | KEGG_DRUG |
| 229369 | RXNORM |
| 4021183 | VANDF |
| C0756085 | UMLSCUI |
| CHEBI:4309 | CHEBI |
| DOL | PDB_CHEM_ID |
| CHEMBL1200937 | ChEMBL_ID |
| DB01764 | DRUGBANK_ID |
| C113826 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10797 | IUPHAR_LIGAND_ID |
| 6581 | INN_ID |
| R9M4FJE48E | UNII |
| 6323289 | PUBCHEM_CID |
| 8300 | MMSL |
| d04456 | MMSL |
| 007888 | NDDF |
| 116111008 | SNOMEDCT_US |
| 387016001 | SNOMEDCT_US |
| 427378005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Synercid | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61570-260 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 350 mg | INTRAVENOUS | NDA | 26 sections |
| Synercid | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61570-260 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 350 mg | INTRAVENOUS | NDA | 26 sections |